Thrombotic Microangiopathy and Renal Failure Exacerbated by ε-Aminocaproic Acid

被引：6

作者：

Mutter, Walter P. ^{[1
]}

Stillman, Isaac E. ^{[1
,2
]}

Dahl, Neera K. ^{[3
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA

[2] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA

[3] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2009年 / 53卷 / 02期

关键词：

Thrombotic microangiopathy; hemolytic anemia; antiphospholipid syndrome; antiphospholipid antibodies; antiphospholipid syndrome nephropathy; systemic lupus erythematosus; epsilon-aminocaproic acid; Amicar; renal failure; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID SYNDROME NEPHROPATHY; ANTIBODY SYNDROME; HEMOLYTIC-ANEMIA; TRANSPLANTATION; RISK;

D O I：

10.1053/j.ajkd.2008.07.023

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

epsilon-Aminocaproic acid (EACA) is used to treat bleeding associated with systemic fibrinolysis, as well as hematuria resulting from urinary tract procedures or tumors. EACA inhibits urokinase and other activators of plasminogen, decreasing the formation of plasmin and inhibiting the breakdown of fibrin.(1.2) EACA-associated renal failure may be caused by obstruction of the upper urinary system by blood clots, hypotension with acute tubular necrosis, renal infarction, and myoglobinuria.) This is the first report of EACA causing renal failure by accelerating a preexisting thrombotic microangiopathic process.

引用

页码：346 / 350

页数：5

共 21 条

[1]

Ardalan MR, 2006, SAUDI J KIDNEY DIS T, V17, P235

[2]

Daugas E, 2002, J AM SOC NEPHROL, V13, P42, DOI 10.1681/ASN.V13142

[3] A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome [J].

Erkan, D ;

Yazici, Y ;

Peterson, MG ;

Sammaritano, L ;

Lockshin, MD .

RHEUMATOLOGY, 2002, 41 (08) :924-929

[4] Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies [J].

Espinosa, G ;

Bucciarelli, S ;

Cervera, R ;

Lozano, M ;

Reverter, JC ;

de la Red, G ;

Gil, V ;

Ingelmo, M ;

Font, J ;

Asherson, RA .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (06) :730-736

[5] KINETICS OF EPSILON-AMINOCAPROIC ACID DISTRIBUTION, ELIMINATION, AND ANTIFIBRINOLYTIC EFFECTS IN NORMAL SUBJECTS [J].

FREDERIKSEN, MC ;

BOWSHER, DJ ;

RUO, TI ;

HENTHORN, TK ;

TSAO, CH ;

GREEN, D ;

ATKINSON, AJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (03) :387-393

[6] THROMBOSIS, RECURRENT FETAL LOSS, AND THROMBOCYTOPENIA - PREDICTIVE VALUE OF THE ANTICARDIOLIPIN ANTIBODY-TEST [J].

HARRIS, EN ;

CHAN, JKH ;

ASHERSON, RA ;

ABER, VR ;

GHARAVI, AE ;

HUGHES, GRV .

ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (11) :2153-2156

[7]

HUGHES GRV, 1986, J RHEUMATOL, V13, P486

[8] Gemcitabine-associated thrombotic microangiopathy [J].

Humphreys, BD ;

Sharman, JP ;

Henderson, JM ;

Clark, JW ;

Marks, PW ;

Rennke, HG ;

Zhu, AX ;

Magee, CC .

CANCER, 2004, 100 (12) :2664-2670

[9] SYSTEMIC LUPUS-ERYTHEMATOSUS COMPLICATED BY THROMBOTIC MICROANGIOPATHY [J].

JAIN, R ;

CHARTASH, E ;

SUSIN, M ;

FURIE, R .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 1994, 24 (03) :173-182

[10] THE MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME [J].

KHAMASHTA, MA ;

CUADRADO, MJ ;

MUJIC, F ;

TAUB, NA ;

HUNT, BJ ;

HUGHES, GRV .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (15) :993-997

← 1 2 3 →